摘要
目的探讨瑞舒伐他汀对急性脑梗死患者血浆超敏C反应蛋白和脂蛋白相关磷脂酶A2的影响。方法 86例急性脑梗死患者随机分为两组,对照组40例,治疗组46例;对照组采用常规治疗,治疗组在常规治疗的基础上加用瑞舒伐他汀20mg,1次/d,口服,两组共治疗30d。治疗前后测定患者血浆超敏C反应蛋白(hs-CRP)和脂蛋白相关磷脂酶A2(Lp-PLA2)的浓度。结果两组治疗后均明显降低血浆hs-CRP和LP-PLA2的表达,并且治疗组降低二者更明显(P<0.05)。两组均未出现严重的不良反应。结论瑞舒伐他汀可以明显降低急性脑梗死患者血浆hs-CRP和Lp-PLA2的表达。
Objective To study the effectiveness of rosuvastatin on high sensitivity C-reactive protein （hs-CRP） and lipoprotein-associated phospholipase A2 （Lp-PLA2） in the serum of patients with acute cerebral infarction. Methods Eighty-six patients with acute cerebral infarction were randomly divided into two groups, the conterol group（ n =40 cases） and the treatment group（ n =46 cases）. The patients in the control group were treated through the conventional treatment and the patients in the treatment group were treated through rosuvastatin plus the conventional treatment. Rosuvastatin was used through orally 20 mg once daily. The hs-CRP and Lp-PLA2 were detected before and after treatment. Results The hs-CRP and Lp-PLk2 in serum of patients were decreased after treatment. There was a significant difference between two groups （ P 〈 0.05 ）. There were not any serious adverse events in the both groups. Conclusion Rosuvastatin can significantly decresse hs-CRP and Lp-PLA2 in the serum of patients with acute erebral infarction.
出处
《中国实用医药》
2012年第20期14-16,共3页
China Practical Medicine
